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Background: The lung of patients with cystic fibrosis (CF) is particularly sensitive to Pseudomonas aeruginosa. This
bacterium plays an important role in the poor outcome of CF patients. During the disease progress, first acquisition
of P. aeruginosa is the key-step in the management of CF patients. Quantitative PCR (qPCR) offers an opportunity to
detect earlier the first acquisition of P. aeruginosa by CF patients. Given the lack of a validated protocol, our goal
was to find an optimal molecular protocol for detection of P. aeruginosa in CF patients.
Methods: We compared two formerly described qPCR formats in early detection of P. aeruginosa in CF sputum
samples: a qPCR targeting oprL gene, and a multiplex PCR targeting gyrB and ecfX genes.
Results: Tested in vitro on a large panel of P. aeruginosa isolates and others gram-negative bacilli, oprL qPCR
exhibited a better sensitivity (threshold of 10 CFU/mL versus 730 CFU/mL), whereas the gyrB/ecfX qPCR exhibited a
better specificity (90% versus 73%). These results were validated ex vivo on 46 CF sputum samples positive for
P. aeruginosa in culture. Ex vivo assays revealed that qPCR detected 100 times more bacterial cells than culture-
based method did.
Conclusion: Based on these results, we proposed a reference molecular protocol combining the two qPCRs, which
offers a sensitivity of 100% with a threshold of 10 CFU/mL and a specificity of 100%. This combined qPCR-based
protocol can be adapted and used for other future prospective studies.
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Pseudomonas aeruginosa is the major pathogen involved
in the decline of lung function in patients with cystic fi-
brosis (CF) [1-5]. Its presence in the lungs is associated
with an increased mortality and morbidity of CF patients
[6]. Early detection of this bacterium from respiratory tract
is determinant because it ensures effective patient manage-
ment [5,7,8]. Indeed, after intermittent colonization by
different strains, once acquired, chronic P. aeruginosa
colonization by mucoid and biofilm-growing isolates is dif-
ficult to eradicate [2,4,9,10]. Thus, the earlier the treatment* Correspondence: hery@univ-brest.fr
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reproduction in any medium, provided the ortoward P. aeruginosa onset, the higher the chance to effi-
ciently control P. aeruginosa [5,7,8].
However, accurate identification of this bacterium in
CF sputum by conventional microbiology techniques is
known to be limited. This can be explained by a large
phenotypic diversity of P. aeruginosa isolates recovered
from CF patients such as loss of pigment production or
exopolysaccharide production. Moreover, Singh et al.
demonstrated that P. aeruginosa can form biofilms in
the airways of CF patients [11]. Biofilms contain bacter-
ial cells that are in a wide range of physiological states.
One of the mechanisms contributing to this physio-
logical heterogeneity includes the adaptation to the local
environmental conditions.
For instance, bacterial cells from the deep layers of
biofilm depleted of oxygen [12] can grow in anaerobicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from biofilms, i.e. in anaerobic conditions, grow hardly
in aerobic conditions on a conventional culture medium
[13]. Another limitation of conventional culture is that
P. aeruginosa can be easily misidentified with closely re-
lated Gram-negative bacilli in CF sputum [14-19].
The use of molecular techniques such as PCR could
improve accurate identification of P. aeruginosa [14-19],
and consequently, its early detection in CF sputum pa-
tients [20-24]. To date, there is no consensus for a uni-
versal protocol for the molecular detection of P.
aeruginosa. Indeed, its genome is known to be highly
polymorphic. Changes that can occur at the genetic level
could compromise the reliability of molecular identifica-
tion techniques. In particular in CF patients lungs, most
of the recovered isolates are hypermutable [2,4,25,26],
and show a high genetic plasticity by acquisition or loss
of genes [27,28]. Since mutations or gene deletions occur
on PCR target sequences, they could decrease the sensitiv-
ity of the method [29]. Moreover, horizontal genetic trans-
fer with other bacterial species present in the CF lung
niche can impact upon the specificity of the PCR [14].
In a prospective multicenter study, we aimed to assess
the role of PCR for the early detection of P. aeruginosa
in CF patients; we evaluated two qPCRs in detection of
P. aeruginosa: a simplex qPCR targeting oprL gene [30],
and a multiplex qPCR, targeting gyrB and ecfX genes
[14]. The sensitivity and the specificity of both qPCRs
were initially evaluated testing a large panel of P.
aeruginosa isolates and closely related non-P. aeruginosa
gram-negative bacilli isolates from CF patients. Then,
the two different qPCRs ability in detection of P.
aeruginosa were tested ex vivo, i.e in CF sputum sam-
ples. Finally, we were able to propose a promising refer-
ence protocol combining these two qPCRs for an
optimal detection of P. aeruginosa in clinical setting.
Methods
Bacterial collection
Thirty-six P. aeruginosa isolates, including mucoid and
non mucoid forms, were obtained from 31 sputum
samples of CF patients and from 5 samples of non CF
patients (blood, n = 1; stool, n = 1; urine, n = 1; sputum,
n = 1; peritoneal fluid, n = 1), attending three French
University Hospitals, the CHRU of Brest (n = 3), the
CHU of Nantes (n = 26), and the GHSR of Saint Pierre,
La Réunion (n = 2). The reference strain P. aeruginosa
CIP 76.110 was also included in the study.
Forty-one closely related non-P. aeruginosa gram-
negative bacillus isolates were collected, including 26
obtained from sputum samples of CF patients, and 15
from clinical samples of non CF patients (n = 13) or envir-
onmental samples (n = 2). Sixteen species were represented:
Achromobacter xylosoxidans (n = 9), P. putida (n = 5),Stenotrophomonas maltophilia (n = 5), Burkholderia
cepacia (n = 4), B. multivorans (n = 3), B. gladioli (n = 2),
Chryseobacterium indologenes (n = 2), Elizabethkingia
meningoseptica (n = 2), P. stutzeri (n = 2), B. cenocepacia
(n = 1), Flavimonas oryzihabitans (n = 1), Pandoraea
pnomenusa (n = 1), P. fluorescens (n = 1), Ralstonia picketti
(n= 1), Roseomonas spp. (n= 1), and Shewanella putrefaciens
(n= 1).
Identification of bacterial isolates was previously
conducted based on phenotypical and morphological cri-
teria (colony morphology, pigmentation, lactose fer-
mentation, oxidase activity checked with 1% tetramethyl
p-phenylenediamine dihydrochloride, sensitivity to antibi-
otics). Atypical P. aeruginosa isolates, for which difficulties
of identification were encountered, were further analyzed
with biochemical tests [API 20NE system (bioMérieux,
Marcy l’Etoile, France), ID 32GN (bioMérieux)], or with
the gram-negative bacillus identification card on VITEK 2
Compact (bioMéreux). All non- P. aeruginosa gram-
negative bacillus isolates were identified by 16S rRNA
gene sequencing as previously described [31].
All bacteria were stored at -80°C. Bacteria from frozen
stocks were grown aerobically at 37°C for 24 to 48 hours
on Muller-Hinton medium (bioMérieux).
P. aeruginosa detection and quantification by sputum
samples culture
CF patients and sample processing
Fourty-six sputa were selected in line with our study ob-
jective. These CF sputum samples have been collected
from 34 patients (median age: 11 years, range: 4-29, 53%
female) attending the CF center of Roscoff (France), be-
tween March 2008 and May 2012. At the time of CF pa-
tients inclusion, all of the patients were P. aeruginosa
free for at least one year. More precisely, according to
the Leeds definition [32], ten of them were never and 22
were free (Table 1). Each sputum sample was mixed with
equal volume of dithiothreitol (Digesteur® Eurobio,
Courtaboeuf, France) and incubated at room temperature
for 30 min. For isolation of P. aeruginosa, liquefied sputa
were immediately processed. For molecular detection
of P. aeruginosa, two one-milliliter aliquots of every li-
quefied sputum were stored at -80°C.
P. aeruginosa isolation
Ten μl of liquefied sputum pure and diluted into 1/1000,
were inoculated and incubated onto several non selective
and selective media for P. aeruginosa isolation, including
Columbia blood agar supplemented with 5% defribinated
horse blood (Oxoid, Dardilly, France), Columbia choc-
olate agar (Oxoid), and cetrimide agar (Oxoid). All
media were incubated aerobically at 37°C for five days
and monitored daily. All different morphotypes of bac-
terial colonies were identified phenotypically with
Table 1 Quantification of Pseudomonas aeruginosa in CF sputum samples by culture and the oprL qPCR and detection




Quantification (CFU/mL) Multiplex qPCR
detection (gyrB/ecfX)Anonymisation number P. aeruginosa category* By culture By oprL qPCR**
003 F 1 0.0E + 00 7.5E + 00 -/-
2 0.0E + 00 1.4E + 03 +/-
3 2.0E + 05 2.7E + 06 +/+
004 F 4 2.0E + 03 1.2E + 05 +/+
010 F 5 1.0E + 04 9.9E + 06 +/+
012 F 6 0.0E + 00 5.0E + 01 +/-
7 0.0E + 00 7.5E + 01 -/-
8 0.0E + 00 2.1E + 02 -/-
9 1.0E + 07 7.8E + 06 +/-
013 F 10 1.0E + 08 4.0E + 09 +/+
014 N 11 1.0E + 06 5.5E + 06 +/+
023 N 12 4.0E + 01 2.5E + 03 +/-
024 F 13 1.0E + 03 1.3E + 05 +/+
025 N 14 5.0E + 04 4.3E + 07 +/+
15 1.0E + 05 3.8E + 03 +/+
026 N 16 2.0E + 06 6.7E + 07 +/+
028 F 17 1.0E + 04 1.1E + 05 +/+
030 F 18 1.0E + 03 1.3E + 04 +/+
031 N 19 1.0E + 06 1.2E + 07 +/+
20 2.0E + 07 1.0E + 08 +/+
034 F 21 4.0E + 02 6.8E + 04 +/+
035 F 22 1.0E + 04 2.7E + 04 +/+
040 F 23 1.0E + 06 1.4E + 06 +/+
041 F 24 1.0E + 02 4.9E + 01 +/-
043 N 25 6.0E + 02 5.6E + 06 +/+
047 N 26 0.0E + 00 1.1E + 03 +/+
27 0.0E + 00 5.3E + 03 +/+
28 1.0E + 07 1.1E + 07 +/+
048 F 29 0.0E + 00 8.1E + 02 +/+
30 4.0E + 01 2.5E + 02 +/+
053 F 31 1.0E + 02 5.1E + 03 +/+
054 N 32 0.0E + 00 2.3E + 01 -/-
33 2.0E + 05 3.7E + 06 +/+
057 F 34 1.0E + 06 2.0E + 01 -/-
060 F 35 4.0E + 06 1.5E + 08 +/+
061 F 36 1.0E + 02 6.1E + 03 +/+
066 F 37 4.0E + 03 3.1E + 04 +/+
38 1.0E + 04 9.5E + 06 +/+
070 N 39 1.0E + 06 9.0E + 07 +/+
072 F 40 4.0E + 04 7.8E + 07 +/+
076 F 41 1.0E + 03 1.5E + 04 +/+
078 F 42 1.0E + 02 2.0E + 04 +/+
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Table 1 Quantification of Pseudomonas aeruginosa in CF sputum samples by culture and the oprL qPCR and detection
by the gyrB/ecfX qPCR (Continued)
202 F 43 1.0E + 05 1.7E + 05 +/-
205 F 44 1.0E + 03 3.3E + 06 +/+
220 F 45 1.0E + 06 2.3E + 08 +/+
256 N 46 1.0E + 03 3.4E + 04 +/+
mean 3.3E + 06 1.2E + 08 NA
*F: Free; N: Never (Lee et al., 2003).
**mean of quantification by oprL qPCR tested in duplicate.
NA: not applicable.
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dase test) followed by mass spectrometry identification
(MicroFlex LT, Bruker Daltonics, Germany) [33,34].
Quantification was conducted based on the colony
forming unit (CFU) counts and the dilution ratio of the
plate.
P. aeruginosa detection and quantification by quantitative
PCR (qPCR)
DNA extraction
For each isolate of the bacterial collection, 1 ml of a 0.5
McFarland suspension was extracted. For each sputum
sample, one of the two 1 ml-aliquots was treated by
5 min of sonication using a bath sonicator (Elamsonic
S10, Singen, Germany). After a 10 min-centrifugation
(5000 g), the pellet was suspended in 200 μl of DNA free
water. Ten μl of the IC2, an internal control provided in
the DICO Extra r-gene™ kit (Argène, Verniolle, France),
were added in each sample and, for each batch of extrac-
tion, in 200 μl of DNA free water as a negative control.
DNA was extracted using the QIAamp DNA Minikit®
(Qiagen, Courtaboeuf, France) according to the instruc-
tions of the manufacturer (“Tissue protocol”) with elu-
tion volumes of 100 μl.
oprL qPCR
oprL qPCR was performed using primers OPRL-F and
OPRL-R and hydrolysis probe oprL-MGB, previouslyTable 2 Primers and probes used in this study for the detecti










*yak = Yakima Yellow; fam = carboxyfluorescein; bhq = block hole quencher.described by Joly et al. [30] (Table 2). The reaction mix
comprised 12.5 μl of Qiagen Quantitect Probe Master
Mix, 0.3 μM of each primer, 0.2 μM of hydrolysis probe
and 4.5 μl of DNA extract, and was made up to a final
reaction volume of 25 μl with water. A negative amplifi-
cation control was used for each batch. For sputum sam-
ples, a standard curve provided a full concentration range
of P. aeruginosa extending from 102 to 106 CFU/mL. Each
qPCR assay was repeated twice, and the mean value of the
quantification was calculated for each duplicate (Table 1).
Cycling was performed on an ABI Prism 7300 Real Time
PCR System (Applied Biosystem, Foster city, Californy),
with an initial hold at 95°C for 15 min, followed by 50 cy-
cles at 95°C for 15 s, and 60°C for 1 min. The oprL-MGB
probe was labelled with carboxyfluorescein (FAM).
gyrB/ecfX qPCR
The P. aeruginosa multiplex PCR was performed using
primers ecfX-F, ecfX-R, gyrB-F, gyrB-F, and hydrolysis
probes ecfX-TM and gyrB-TM, previously described by
Anuj in 2009 [14] (Table 2). The reaction mix comprised
12.5 μl of Qiagen Quantitect Probe Master Mix, 0.4 μM
of each primer, 0.16 μM of each hydrolysis probe, and
4.5 μl of DNA extract and was made up to a final reac-
tion volume of 25 μl with free DNA water. All qPCR re-
action plates contained negative amplification controls.
For reaction plates containing sputum samples, a broad-











Table 3 Bacterial species responsible for false positive
amplifications with the oprL and gyrB/ecfX qPCRs
Species Number of isolates








6/9 + - / -
Burkholderia
cenocepacia
1/1 + - / -
Burkholderia
multivorans
1/3 + - / -
Chryseobacterium
indologenes
1/2 - + / +
Elizabethkingia
meningoseptica
1/2 + - / -
Flavimonas
oryzihabitans
1/1 - + / +
Pseudomonas
putida
1/5 - - / +
Pseudomonas
stutzeri
1/2 - - / +
Roseomonas spp. 1/1 + - / -
Stenotrophomonas
maltophilia
1/5 + - / -
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ABI Prism 7300 Real Time PCR System (Applied
Biosystem), with an initial hold at 95°C for 15 min,
followed by 50 cycles at 95°C for 15 s, and 60°C for 1 min.
The gyrB-TM probe was labelled with carboxyfluorescein
(FAM), whereas the ecfX-TM probe was labeled with a
Yakima Yellow fluorophore, enabling the reaction to be
distinguished using the ABI 7300 FAM and JOE detection
channels, respectively. Results were analyzed by the 7300
System SDS logiciel (Applied biosystem). The gyrB/ecfX
qPCR was considered positive when at least one of the
two target genes was detected.
DICO extra r-gene amplification
Ten microliter of extracted sputum samples were dis-
tributed in 15 μl of the DICO Extra r-gene premix (DP2,
Argène) with 0.1 μl of the HotStarTaq™ (Qiagen). The
amplification program recommended by the manufac-
turer was applied on the automate ABI Prism 7300 Real
Time PCR System (Applied Biosystem). The validation
of both DNA isolation and amplification procedures, as
well as the samples result interpretation, were conducted
according to the instructions by Argene.
Determination of the lower detection threshold
To determine the lower detection threshold, six dilution
ranges were realized with six different P. aeruginosa iso-
lates. One range was prepared with the reference strain
(CIP 76.110), two with a mucoid and a non-mucoid iso-
lates from a sputum sample of a CF patient, and three
with three isolates from three non-CF patients (urine,
n = 1; blood, n = 1; stool, n = 1). Ten fold iterative dilu-
tions from 0.5 McFarland calibrated P. aeruginosa suspen-
sions provided a full concentration range extending from
100 to 108 CFU/mL. The nine dilutions of the range were
tested 30 times. To determine the exact inoculum of each
dilution range, a plate counting was carried out on a
Mueller-Hinton medium (bioMérieux) incubated from 24
to 48 hours at 30°C. A mean of the results was calculated
taking into account the sum of all assays.
Ethics
The Comité de Protection des Personnes Ouest VI ap-
proved the protocol. All of the patients and their rela-
tives gave written informed consent. The collection of
archival specimens was registered with the French
Ministry of Research and the Agence Régionale de
l’Hospitalisation, No. DC-2008-214.
Results
In vitro characteristics of the oprL and gyrB/ecfX qPCR
Sensitivity
The two qPCRs showed 100% sensitivity. At the concen-
tration of 106 CFU/mL, all the 37 P. aeruginosa isolateswere detected by the two qPCRs. The cycle treshold
(Cq) mean was 24.8 and 24/28.2 respectively for the
oprL qPCR and the gyrB/ecfX qPCR.Specificity
The specificity of the oprL qPCR was evaluated at 73%.
At the concentration of 106 CFU/mL, eleven isolates out
of the 41 non-P. aeruginosa gram-negative bacillus iso-
lates, corresponding to six different species, were ampli-
fied by the oprL qPCR. The six species responsible for
cross-reactions were A. xylosoxidans, B. cenocepacia, B.
multivorans, E. meningoseptica, Roseomonas spp., and S.
maltophilia (Table 3). By considering the gyrB/ecfX
qPCR positive when at least one of the two targeted
genes was amplified, the specificity was calculated at
90%. Four out of the 41 isolates corresponding to four
different species induced false positive reactions in at
least one of their assays (Table 3): C. indologenes, F.
oryzihabitans, P. putida and P. stutzeri. No species
cross-reacted with both qPCRs. In this manner, combin-
ing oprL and gyrB/ecfX amplifications allowed achieving
100% specificity.Lower detection threshold
The lower detection threshold of the oprL qPCR was
evaluated at 10 CFU/mL. Given a positive multiplex
PCR when at least one of the two probes was detected,
the detection threshold of the gyrB/ecfX qPCR was eval-
uated at 730 CFU/mL.
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P. aeruginosa in CF sputa by the two qPCRs
The oprL qPCR detected P. aeruginosa in all the 46 CF
sputum samples. The multiplex PCR failed to detect the
bacterium in five samples. The mean quantification of
P. aeruginosa of these samples was evaluated at
67.1 CFU/mL, i.e. under the lower detection threshold
of the gyrB/ecfX qPCR. For six of the 46 samples, only
one probe (gyrB) was detected positive. Comparison of
the results of P. aeruginosa quantification in CF sputum
samples by culture and oprL qPCR is reported in
Table 1. For 37 out of the 46 sputum samples tested,
the quantification found by PCR is at least one log
above the one found by culture. In average, for the 46
tested sputum samples, the molecular quantification of
P. aeruginosa was two logs higher than the conven-
tional culture quantification (1.2E + 08 CFU/mL versus
3.3E + 06 CFU/mL).
Consistency between in vitro and ex vivo experiments
The theoretical threshold calculated from in vitro experi-
ments was totally consistent with the observed threshold
from ex vivo experiments. Indeed, oprL qPCR assays
performed ex vivo identified one hundred times more
bacterial cells than culture-based methods did. Thus, the
theoretical lower detection threshold of oprL qPCR of
10 CFU/mL calculated from in vitro cultures is equiva-
lent to a threshold of 1E + 03 CFU/mL if applied ex vivo.
This was verified on 9 culture-/PCR + samples for which
the quantification by oprL qPCR retrieved a mean of
quantification of 997.3 CFU/mL.
The theoretical lower detection of the multiplex qPCR
was found at 7.3E + 02 CFU/mL in vitro. Ex vivo, the
amplification conducted on the sputum samples showed
a positive signal for at least one target (gyrB or ecfX) for
all of the P. aeruginosa-positive sputa with quantification
above 7.3E + 02 CFU/mL (n = 38). On the contrary,
below 7.3E + 02 CFU/mL, the majority (5 of 8 samples)
of the sputa that were P. aeruginosa-positive by oprL
PCR, were P. aeruginosa-negative by multiplex PCR.
To conclude, the theoretical thresholds of both qPCRs
were verified on the sputum samples.
Discussion and conclusion
Several studies have suggested that qPCR is superior to
culture for detecting early colonization of P. aeruginosa
in CF sputum [20,22-24]. Today, the main goal is to
have an optimal protocol as the gold standard for the
molecular detection of P. aeruginosa. Therefore, we
performed in vitro and ex vivo evaluation of two qPCRs,
one targeting the oprL gene and the other targeting sim-
ultaneously gyrB and ecfX genes [14,30]. Numerous
DNA targets have been described for the amplification
of P. aeruginosa [15,17,19,34-36], of these threehousekeeping genes, oprL, gyrB and ecfX have been
reported to be reliable targets in the detection of P.
aeruginosa [14,19,30,35].
The first criterion for an optimal technique in early
detection of P. aeruginosa in CF sputum is related to the
choice of the PCR format and its optimization. Today,
the DNA molecules counting of a particular sequence in
a complex sample can be achieved with exceptional ac-
curacy and sensitivity sufficient to detect a single mol-
ecule [36]. As underlined by Deschagt et al. [35], the
choice of PCR format may influence the performance of
the molecular detection. We chose a probe-based assay,
which is known to be more sensitive and specific than
the SYBR Green-based qPCR [35].
The second criterion is a good sensitivity to prevent
false negative results. Despite wide genetic variability of
P. aeruginosa isolates recovered from CF patients
[2,4,25-28], results of previous studies aiming at
detecting P. aeruginosa by PCR have been encouraging.
In our study, both evaluated qPCRs showed an excellent
sensitivity covering all the tested panel of P. aeruginosa
isolates. Focusing on the lower detection threshold, the
difference was significant between the two qPCR assays
with a detection threshold of 10 CFU/mL for the oprL
qPCR versus 730 CFU/mL for the multiplex PCR. The
sensitivity of the in vitro oprL qPCR in our study was
higher than that recommended by the French guidelines,
i.e. a detection threshold of 102 CFU/mL for CF sputum
sample [37].
The third criterion needed for early P. aeruginosa de-
tection technique, in particular, for molecular one, is to
have a high specificity to prevent false positive amplifica-
tion. When looking at a large panel of genes described
in the literature e.g. oprI, oprL, rrl, ecfX, gyrB, or rrs, spe-
cificity varied from 74% to 100% [14,17,34-36,38]. In our
study, specificity of the oprL qPCR was evaluated at 73%
versus 90% for the multiplex PCR. Four previous studies
have tested the specificity of the oprL primer pairs and
found different values ranging from 87% to 100%
[22,34,35,38]. Again, previous studies looking at gyrB
and ecfX genes found a better specificity (100%) than in
our study [14,35]. Different reasons could explain these
discrepancies. Firstly, our specificity could have been
influenced by a larger panel of closely related non P.
aeruginosa gram-negative bacilli (41 isolates including
16 different species). Secondly, all the bacterial isolates
(except one reference strain) were recovered from clin-
ical samples (CF or non CF) or from environmental
samples. These isolates, which were recovered from CF
could have undergone genetic exchange with other spe-
cies in the natural CF microenvironment, especially P.
aeruginosa, influencing the specificity of the molecular
method [38]. Thus, specificity in previous studies could
have been overestimated [14,34,35,38]. As highlighted by
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for the multiplex PCR may be explained by the fact that
we amplified at least 2 DNA targets. The use of two
probes simultaneously seems to improve the specificity,
providing at the same time the detection and the con-
firmation of the presence of P. aeruginosa [14,19]. Inter-
estingly, our bacterial species that cross-reacted with the
oprL qPCR did not do so when oprL qPCR was com-
bined with the multiplex PCR thus allowing 100%
specificity.
These results were successfully validated by the spu-
tum samples of CF patients from the never or free cat-
egories according to the definition of Leeds [32]. The
ex vivo experiments put forward a significant difference
between the culture-based quantification and the qPCR-
based quantification. In average, the qPCR detected 100
times more CFU of P. aeruginosa than the culture did.
This could be explained by different hypotheses. First,
the difference in utilized sputum volumes contributes to
this discrepancy. Indeed, only 10 μl were cultured
whereas 1 ml was extracted for the qPCR. The lowest
concentration that theoretically can be detected by
qPCR equals the presence of one genome (i.e. equivalent
to one CFU) per qPCR reaction mixture. Using 1 ml of
10-fold concentrated sputum by centrifugation and ex-
traction (elution volume of 100 μl) and 4.5 μl for the
PCR reaction (final volume of 25 μl), the detection limit
of our molecular diagnosis is ≈22 CFU/mL. InFigure 1 Proposal of a molecular protocol integrating two qPCR form
Pseudomonas aeruginosa in sputum samples of patients with cystic fi
sensitivity. In case of a doubtful or a positive result, the gyrB/ecfX qPCR is a
account the quantification found with oprL qPCR. Below the detection thre
Conversely, beyond this threshold, the gyrB/ecfX qPCR prevails over the opcomparison, the lowest concentration that theoretically
can be detected by culture is 100 CFU/mL.
Second, given the phenotypic diversity of P. aeruginosa
isolates and the large diversity of species found in pul-
monary microbiota, the detection of P. aeruginosa by
culture in CF sputum is a hard task [14-19]. Moreover,
culture in aerobic conditions can fail in the detection of
some isolates adapted to anaerobic conditions of the CF
lung niche [13], or of non-cultivable isolates present in
the bacterial biofilm [39].
Another explanation could be that qPCR detects P.
aeruginosa DNA, i.e. not only live bacteria but also dead
cells [40]. As CF patients are chronically treated with anti-
biotics, one can suppose that dead bacteria are signifi-
cantly present in the pulmonary tract. In a study lead by
Deschaght et al. in 2009, no difference in sensitivity be-
tween culture and oprL qPCR was found [41]. Their study
was conducted on eight artificial P. aeruginosa-positive
sputum pre-liquefied samples thus skipping the sample
homogenization step, one of the cornerstones in
amplification-based technique. Our ex vivo application of
the two qPCR assays with real samples took into account
the sample homogenization. It also put forward the im-
portance of having a controlled amplification assay in par-
ticular to avoid false negatives due to inhibitors or a bad
extraction. Indeed, the DNA-extraction method has been
shown to be a critical step in the PCR performances [41].
In our study, we chose the DICO Extra r-gene kit, a totallyats (targeting oprL and gyrB/ecfX genes) for an early detection of
brosis. The oprL qPCR is applied in screening because of its good
pplied in a second time. Interpretation of the gyrB/ecfX qPCR takes into
shold of 730 CFU/mL, the oprL qPCR prevails over the gyrB/ecfX qPCR.
rL qPCR.
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contamination during procedure handling, and allows to
test extraction and amplification at the same time.
Altogether, our study showed that the oprL qPCR of-
fers a good sensitivity whereas the multiplex PCR offers
a good specificity. Based on these data, we decided to
combine these two qPCR assays and proposed a molecu-
lar protocol for an optimal detection of P. aeruginosa by
qPCR in CF sputum as follows (Figure 1). The oprL
qPCR can be applied in screening because of its good
sensitivity. In case of a doubtful or a positive result, we
can proceed to the multiplex PCR. Interpretation of the
multiplex PCR takes into account the quantification
found with oprL PCR. Below the detection threshold of
730 CFU/mL, the oprL qPCR prevails over the multiplex
PCR. Conversely, beyond this threshold, the multiplex
PCR prevails over the oprL qPCR. Overall, this combined
molecular protocol offers a sensitivity of 100% with a
threshold of 10 CFU/mL and a specificity of 100%.
This qPCR-based combined protocol can be adapted
for instance in a subgroup of non-sputum producing pa-
tients and used for other future prospective studies. In-
deed, the initial colonization of P. aeruginosa often
occurs in CF patients who do not produce sputum (e.g.
mainly children). This qPCR format should therefore be
tested on the sample secretions routinely obtained from,
e.g. deep throat swabs or endolaryngeal suction.
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